A feed-forward loop between nuclear translocation of CXCR4 and HIF-1α promotes renal cell carcinoma metastasis.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
02 2019
Historique:
received: 19 02 2018
accepted: 24 07 2018
revised: 24 05 2018
pubmed: 5 9 2018
medline: 27 2 2019
entrez: 5 9 2018
Statut: ppublish

Résumé

CXC chemokine receptor 4 (CXCR4) has been suggested to play a critical role in cancer metastasis. Some studies have described CXCR4 nuclear localization in metastatic lesions of renal cell carcinoma (RCC), which has been suggested to be correlated with cancer metastasis. However, the underlying mechanism and clinical significance of CXCR4 nuclear localization remains unknown. Here, we show that CXCR4 nuclear localization is more likely to occur in RCC tissues, especially in metastases, and is associated with poor prognosis. CXCR4 nuclear localization requires its nuclear localization sequence (NLS, residues 146-RPRK-149). After the mutation of NLS in CXCR4, CXCR4 nuclear localization in RCC cells is lost. Nuclear localization of CXCR4 promoted RCC tumorigenicity both in vitro and in vivo. Mechanistically, we found that CXCR4 and hypoxia-inducible factor-1α (HIF-1α) colocalized in RCC cells and interacted with each other. Moreover, CXCR4 nuclear localization promoted nuclear accumulation of HIF-1α, thereby promoting the expression of genes downstream of HIF-1α. Reciprocally, nuclear HIF-1α promoted CXCR4 transcription, thus forming a feed-forward loop. Subcellular CXCR4 and HIF-1α expression levels were independent adverse prognostic factors and could be combined with TNM stage to generate a predictive nomogram of the clinical outcome of patients with RCC. Therefore, our findings indicate that CXCR4 nuclear translocation plays a critical role in RCC metastasis and may serve as a prognostic biomarker and potential therapeutic target.

Identifiants

pubmed: 30177838
doi: 10.1038/s41388-018-0452-4
pii: 10.1038/s41388-018-0452-4
pmc: PMC6367212
doi:

Substances chimiques

CXCR4 protein, human 0
HIF1A protein, human 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
Neoplasm Proteins 0
Receptors, CXCR4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

881-895

Références

Oncol Rep. 2009 Dec;22(6):1333-9
pubmed: 19885584
Asian J Urol. 2016 Oct;3(4):286-292
pubmed: 29264197
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
J Oncol. 2014;2014:808012
pubmed: 24659999
Mol Pharmacol. 2014 May;85(5):651-7
pubmed: 24569087
Sci Rep. 2017 Aug 3;7(1):7190
pubmed: 28775317
Cell Biosci. 2017 Nov 13;7:62
pubmed: 29158891
Pharmacol Rev. 2000 Mar;52(1):145-76
pubmed: 10699158
Clin Exp Metastasis. 2005;22(1):39-46
pubmed: 16132577
Biochim Biophys Acta. 2007 Apr;1768(4):952-63
pubmed: 17169327
Ann Oncol. 2007 Jun;18(6):1021-9
pubmed: 17351259
J Exp Med. 2003 Nov 3;198(9):1391-402
pubmed: 14597738
Clin Exp Metastasis. 2009;26(8):1049-54
pubmed: 19859817
Adv Drug Deliv Rev. 2009 Jul 2;61(7-8):623-32
pubmed: 19409433
Int J Colorectal Dis. 2010 Oct;25(10):1185-91
pubmed: 20607251
Oncol Rep. 2016 Nov;36(5):2681-2688
pubmed: 27634189
FASEB J. 1999 Oct;13(13):1699-710
pubmed: 10506573
Nature. 2003 Sep 18;425(6955):307-11
pubmed: 13679920
Cancer Treat Rev. 2003 Aug;29(4):297-307
pubmed: 12927570
J Urol. 1999 Feb;161(2):381-6; discussion 386-7
pubmed: 9915408
Lab Invest. 2006 Dec;86(12):1221-32
pubmed: 17075581
Mol Cancer. 2006 Nov 03;5:56
pubmed: 17083723
Pathol Res Pract. 2010 Oct 15;206(10):712-5
pubmed: 20646838
J Cell Biol. 1997 Nov 3;139(3):651-64
pubmed: 9348282
Br J Cancer. 2008 May 20;98(10):1682-9
pubmed: 18443596
FEBS Lett. 1998 Apr 17;426(2):271-8
pubmed: 9599023
Br J Cancer. 2009 May 5;100(9):1444-51
pubmed: 19352387
Cell Metab. 2018 Feb 6;27(2):281-298
pubmed: 29129785
Tumour Biol. 2014 May;35(5):4589-97
pubmed: 24464926
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
PLoS One. 2013;8(2):e57194
pubmed: 23468933
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520

Auteurs

Yi Bao (Y)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.

Zhixiang Wang (Z)

Department of Urology, the 458th Hospital of PLA, Guangzhou, 510602, China.

Bing Liu (B)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.

Xin Lu (X)

Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.

Ying Xiong (Y)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.

Jiazi Shi (J)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.

Peng Li (P)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Department of Urology, No.153 Hospital of PLA, Zhengzhou, 450042, Henan, China.

Junming Chen (J)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Department of Urology, Henan Provincial Corps Hospital of Chinese People's Armed Police Forces, Zhengzhou, 450052, Henan, China.

Zongqin Zhang (Z)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.

Ming Chen (M)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.

Linhui Wang (L)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China. wanglinhui@smmu.edu.cn.

Zhenjie Wu (Z)

Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China. wuzhenjie17@smmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH